Cargando…

非小细胞肺癌脑膜转移的临床病理特征及预后分析

BACKGROUND AND OBJECTIVE: Leptomeningeal metastases (LM) is one of the most serious complications of advanced non-small cell lung cancer (NSCLC) due to the lower quality of life and poor prognosis.The aim of this study is to analyze the clinicopathological features and prognosis of patients with LM...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972984/
https://www.ncbi.nlm.nih.gov/pubmed/27561804
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.09
_version_ 1783326514191794176
collection PubMed
description BACKGROUND AND OBJECTIVE: Leptomeningeal metastases (LM) is one of the most serious complications of advanced non-small cell lung cancer (NSCLC) due to the lower quality of life and poor prognosis.The aim of this study is to analyze the clinicopathological features and prognosis of patients with LM from NSCLC (NSCLC-LM). METHODS: Clinical data of 3 patients with NSCLC-LM collected from January 2015 to June 2016 were analyzed with a brief review. RESULTS: All 3 patients had adenocarcinoma histology harboring epidermal growth factor receptor (EGFR) exon 21 point mutations (m).Of the 3 cases, 1 was male, 2 were female.The mean age was 61.3 years (range, 59-64 years).The main clinical manifestations and positive physical examination included headache (3/3), dizziness (3/3), nausea (3/3) and vomiting (3/3), epilepsy (2/3), diplopia (1/3), hearing loss (1/3) and meningeal stimulation sign (3/3).The median time from symptom to diagnosis of LM was 2.3 months (range, 1 to 4 months).Except 1 patient with lung cancer and LM diagnosised at the same time, the other 2 cases received the diagnosis of LM after tyrosine kinase inhibitors (TKIs) therapy or chemotherapy respectively, the median time from diagnosis of NSCLC to LC was 8.5 months.The brain enhanced magnetic resonance imaging (MRI) manifestations of all 3 cases revealed linear meningeal enhancement.Cerebrospinal fluid in 3 cases were positive cytology in whom two cases had EGFR exon 21 L858R mutations, consistenting with the lung tissue.The symptom of the 2 cases improved after TKIs therapy, and temozolomide was used as supplement of 1 case of which the progression-free survival (PFS) and overall survival (OS) was 4.9 months and 13.9 months respectively. CONCLUSION: Lung adenocarcinoma with sensitive EGFR mutations are likely to appear LM.Lacking of typical symptoms, NSCLC-LM was easily to be missed and misdiagnosed.TKIs therapy combined with temozolomide may be effective therapies for EGFRm-NSCLC-LM patients.
format Online
Article
Text
id pubmed-5972984
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59729842018-07-06 非小细胞肺癌脑膜转移的临床病理特征及预后分析 Zhongguo Fei Ai Za Zhi 肺癌脑转移专题 BACKGROUND AND OBJECTIVE: Leptomeningeal metastases (LM) is one of the most serious complications of advanced non-small cell lung cancer (NSCLC) due to the lower quality of life and poor prognosis.The aim of this study is to analyze the clinicopathological features and prognosis of patients with LM from NSCLC (NSCLC-LM). METHODS: Clinical data of 3 patients with NSCLC-LM collected from January 2015 to June 2016 were analyzed with a brief review. RESULTS: All 3 patients had adenocarcinoma histology harboring epidermal growth factor receptor (EGFR) exon 21 point mutations (m).Of the 3 cases, 1 was male, 2 were female.The mean age was 61.3 years (range, 59-64 years).The main clinical manifestations and positive physical examination included headache (3/3), dizziness (3/3), nausea (3/3) and vomiting (3/3), epilepsy (2/3), diplopia (1/3), hearing loss (1/3) and meningeal stimulation sign (3/3).The median time from symptom to diagnosis of LM was 2.3 months (range, 1 to 4 months).Except 1 patient with lung cancer and LM diagnosised at the same time, the other 2 cases received the diagnosis of LM after tyrosine kinase inhibitors (TKIs) therapy or chemotherapy respectively, the median time from diagnosis of NSCLC to LC was 8.5 months.The brain enhanced magnetic resonance imaging (MRI) manifestations of all 3 cases revealed linear meningeal enhancement.Cerebrospinal fluid in 3 cases were positive cytology in whom two cases had EGFR exon 21 L858R mutations, consistenting with the lung tissue.The symptom of the 2 cases improved after TKIs therapy, and temozolomide was used as supplement of 1 case of which the progression-free survival (PFS) and overall survival (OS) was 4.9 months and 13.9 months respectively. CONCLUSION: Lung adenocarcinoma with sensitive EGFR mutations are likely to appear LM.Lacking of typical symptoms, NSCLC-LM was easily to be missed and misdiagnosed.TKIs therapy combined with temozolomide may be effective therapies for EGFRm-NSCLC-LM patients. 中国肺癌杂志编辑部 2016-08-20 /pmc/articles/PMC5972984/ /pubmed/27561804 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.09 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 肺癌脑转移专题
非小细胞肺癌脑膜转移的临床病理特征及预后分析
title 非小细胞肺癌脑膜转移的临床病理特征及预后分析
title_full 非小细胞肺癌脑膜转移的临床病理特征及预后分析
title_fullStr 非小细胞肺癌脑膜转移的临床病理特征及预后分析
title_full_unstemmed 非小细胞肺癌脑膜转移的临床病理特征及预后分析
title_short 非小细胞肺癌脑膜转移的临床病理特征及预后分析
title_sort 非小细胞肺癌脑膜转移的临床病理特征及预后分析
topic 肺癌脑转移专题
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972984/
https://www.ncbi.nlm.nih.gov/pubmed/27561804
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.09
work_keys_str_mv AT fēixiǎoxìbāofèiáinǎomózhuǎnyídelínchuángbìnglǐtèzhēngjíyùhòufēnxī
AT fēixiǎoxìbāofèiáinǎomózhuǎnyídelínchuángbìnglǐtèzhēngjíyùhòufēnxī
AT fēixiǎoxìbāofèiáinǎomózhuǎnyídelínchuángbìnglǐtèzhēngjíyùhòufēnxī
AT fēixiǎoxìbāofèiáinǎomózhuǎnyídelínchuángbìnglǐtèzhēngjíyùhòufēnxī
AT fēixiǎoxìbāofèiáinǎomózhuǎnyídelínchuángbìnglǐtèzhēngjíyùhòufēnxī
AT fēixiǎoxìbāofèiáinǎomózhuǎnyídelínchuángbìnglǐtèzhēngjíyùhòufēnxī
AT fēixiǎoxìbāofèiáinǎomózhuǎnyídelínchuángbìnglǐtèzhēngjíyùhòufēnxī